Biogen Sets A High R&D Bar With A Pipeline That Extends Well Beyond MS
The company has recruited top talent and is studying some of the most challenging areas within pharma, including neurodegenerative and rare diseases, but the high-risk, high-reward nature of the pipeline has spooked some investors.
You may also be interested in...
CEO George Scangos built Biogen into an innovative biotech, but his departure, coming as the company dusts itself off after a fall from glory, increased speculation Biogen could become a takeout target.
After an impressive commercial run for Biogen Idec, with four drug launches in two years, it’s up to R&D to deliver more innovative medicines. The bar is high in the areas of neurology Biogen is exploring; Chief Medical Officer Alfred Sandrock discussed the company’s R&D momentum in a recent interview.
Orna is retaining full ownership of its "crown jewel," in situ CAR programs for cancer. CEO Tom Barnes talked to Scrip about the deal and Orna's business strategy.